€38.99
0.35%
Xetra, Dec 23, 05:37 pm CET
ISIN
NL0000240000
Symbol
QIA

Qiagen Target price 2025 - Analyst rating & recommendation

Qiagen Classifications & Recommendation:

Buy
50%
Hold
50%

Qiagen Price Target

Target Price €43.31
Price €38.99
Potential 11.09%
Number of Estimates 18
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €43.31. This is 11.09% higher than the current stock price. The highest price target is €50.83 30.37% , the lowest is €38.60 1.00% .
A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 11.09% . Most analysts recommend the Qiagen stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2030


Dec '24 2025
Estimates
Revenue Billion € 1.68 1.80
0.66% 7.07%
EBITDA Margin 25.51% 36.93%
9.92% 44.79%
Net Margin 4.23% 24.66%
75.67% 483.55%

25 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 2.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 5.77% , the lowest is €1.7b 3.78% .

This results in the following potential growth metrics:

Revenue Estimates

2024 €1.7b 0.66%
2025 €1.8b 7.07%
2026 €1.9b 6.14%
2027 €2.0b 6.27%
2028 €2.2b 10.38%
2029 €2.4b 7.93%
2030 €2.8b 17.88%

22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €663m . This is 37.93% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €738m 53.19% , the lowest is €576m 19.69% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €429m 10.64%
2025 €663m 55.02%
2026 €710m 6.98%
2027 €774m 9.01%
2028 €837m 8.14%
2029 €884m 5.64%

EBITDA Margin

2024 25.51% 9.92%
2025 36.93% 44.79%
2026 37.22% 0.79%
2027 38.18% 2.58%
2028 37.40% 2.04%
2029 36.61% 2.11%

25 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €443m . This is 28.86% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €460m 33.51% , the lowest is €424m 23.04% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €71.0m 75.51%
2025 €443m 524.83%
2026 €477m 7.58%
2027 €523m 9.65%
2028 €585m 12.00%
2029 €645m 10.11%

Net Margin

2024 4.23% 75.67%
2025 24.66% 483.55%
2026 25.00% 1.38%
2027 25.79% 3.16%
2028 26.17% 1.47%
2029 26.70% 2.03%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030


Dec '24 2025
Estimates
Earnings Per Share 0.32 2.04
75.38% 537.50%
P/E 19.08
EV/Sales 4.86

25 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.04 . This is 30.77% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.12 35.90% , the lowest is €1.95 25.00% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €0.32 75.38%
2025 €2.04 537.50%
2026 €2.20 7.84%
2027 €2.41 9.55%
2028 €2.70 12.03%
2029 €2.97 10.00%

P/E ratio

Current 24.99 79.61%
2025 19.08 23.66%
2026 17.74 7.02%
2027 16.18 8.79%
2028 14.44 10.75%
2029 13.12 9.14%

Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.86 and an P/S ratio of 4.66 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.97 13.26%
2025 4.86 2.16%
2026 4.58 5.78%
2027 4.31 5.90%
2028 3.91 9.41%
2029 3.62 7.34%
2030 3.07 15.17%

P/S ratio

Current 4.76 13.47%
2025 4.66 2.23%
2026 4.39 5.78%
2027 4.13 5.90%
2028 3.74 9.41%
2029 3.47 7.34%
2030 2.94 15.17%

Current Qiagen Upgrades & Downgrades

Analyst Rating Action Date
Barclays
Overweight
Overweight
Unchanged Dec 15 2025
Citigroup
Buy
Neutral
Downgrade Dec 11 2025
Barclays
Overweight
Overweight
Unchanged Oct 02 2025
UBS
Neutral
Neutral
Unchanged Aug 07 2025
B of A Securities
Buy
Buy
Unchanged Jun 26 2025
Barclays
Overweight
Initiated Jun 24 2025
Baird
Neutral
Neutral
Unchanged Apr 21 2025
Analyst Rating Date
Unchanged
Barclays:
Overweight
Overweight
Dec 15 2025
Downgrade
Citigroup:
Buy
Neutral
Dec 11 2025
Unchanged
Barclays:
Overweight
Overweight
Oct 02 2025
Unchanged
UBS:
Neutral
Neutral
Aug 07 2025
Unchanged
B of A Securities:
Buy
Buy
Jun 26 2025
Initiated
Barclays:
Overweight
Jun 24 2025
Unchanged
Baird:
Neutral
Neutral
Apr 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today